# Emergent BioSolutions Inc.: Form 10-Q for the period ended Mar 31, 2016

- Company: [Emergent BioSolutions Inc.](/companies/ebs.md) (CIK 1367644)
- Form: 10-Q
- Filed: 2016-05-06
- Accepted by EDGAR: May 6, 2016, 13:42 ET
- Period: 2016-03-31
- Accession: 0001367644-16-000064
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1367644/000136764416000064/form10-q033116.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1367644/000136764416000064/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-01-01 to 2016-03-31 | $111.0m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-01-01 to 2016-03-31 | $28.5m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months, 2016-01-01 to 2016-03-31 | $34.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2016-01-01 to 2016-03-31 | $39.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-01-01 to 2016-03-31 | $8.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-01-01 to 2016-03-31 | $1.5m | us-gaap:InterestExpense |
| Income tax | 3 months, 2016-01-01 to 2016-03-31 | $3.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-01-01 to 2016-03-31 | $4.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-01-01 to 2016-03-31 | $0.10 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-01-01 to 2016-03-31 | $0.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-01-01 to 2016-03-31 | 48,359,892 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2016-01-01 to 2016-03-31 | $37.8m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 3 months, 2016-01-01 to 2016-03-31 | $18.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-03-31 | $341.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-03-31 | $528.2m | us-gaap:AssetsCurrent |
| Total assets | at 2016-03-31 | $1.04bn | us-gaap:Assets |
| Current liabilities | at 2016-03-31 | $90.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-03-31 | $368.9m | us-gaap:Liabilities |
| Long-term debt | at 2016-03-31 | $247.2m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2016-03-31 | $667.0m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1367644/000136764416000064/form10-q033116.htm

Filed May 6, 2016.
Source: SEC EDGAR, the filing index for accession 0001367644-16-000064. Last ingested by Listed: Nov 4, 2026, 16:51 ET. No prices; not investment advice.
